Radiopharmaceutical firm Piramal Imaging said four studies of its florbetaben PET agent will be presented at the European Association of Nuclear Medicine (EANM) congress in Lyon, France.
Florbetaben is currently being reviewed by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for use in the visual detection of beta amyloid in the brains of adults with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline.
The four scientific presentations highlight the agent's potential role in improving the accuracy of diagnosing Alzheimer's disease, the company said.
